Comparison of PD-L1 expression and MMR status between primary and matched metastatic lesions in patients with cervical cancer-Reference-Cited by-同舟云学术

Comparison of PD-L1 expression and MMR status between primary and matched metastatic lesions in patients with cervical cancer

Published:2023-06-28 Issue:13 Volume:149 Page:11397-11410
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Liu Huizhen,Sun Lixin,Lian Jing,Wang Lixia,Xi Yanfeng,Zhao Guohai,Wang Jiahong,Lan Xiaoyu,Du Haiyan,Yan Wenxia,Bu Peng,Wang Ping,Moore Anna^ORCID,Zhao Hongwei

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-023-05020-6.pdf

Reference43 articles.

1. Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, Huh WK, Lurain Iii JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Sisodia R, Tillmanns T, Ueda S, Urban R, Wyse E, McMillian NR, Motter AD (2020) NCCN guidelines insights: cervical cancer, version 1.2020. J Natl Compr Cancer Netw 18(6):660–666

2. Aird JJ, Steel MJ, Chow C, Ho J, Wolber R, Gilks CB, Hoang LN, Schaeffer DF (2020) Should you repeat mismatch repair testing in cases of tumour recurrence? An evaluation of repeat mismatch repair testing by the use of immunohistochemistry in recurrent tumours of the gastrointestinal and gynaecological tracts. Histopathology 76(4):521–530

3. Callea M, Albiges L, Gupta M, Cheng SC, Genega EM, Fay AP, Song J, Carvo I, Bhatt RS, Atkins MB, Hodi FS, Choueiri TK, McDermott DF, Freeman GJ, Signoretti S (2015) Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma. Cancer Immunol Res 3(10):1158–1164

4. Chao X, Song X, Wu H, You Y, Wu M, Li L (2021) Selection of treatment regimens for recurrent cervical cancer. Front Oncol 11:618485

5. Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, Zhang Y, He X, Zhou T, Qin T, Huang Y, Yi X, Zhang L (2015) Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J Thorac Oncol 10(6):910–923

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The emerging and challenging role of PD-L1 in patients with gynecological cancers: An updating review with clinico-pathological considerations;Gynecologic Oncology;2024-05